Nektar, Cellular Biomedicine Enter New Clinical Study Collaboration
(RTTNews) - Nektar Therapeutics (NKTR) announced Wednesday that it has entered into a new clinical study collaboration with Cellular Biomedicine Group Inc. (CBMG).
The study will evaluate Nektar's NKTR-255, a novel interleukin-15 (IL-15) receptor agonist, in combination with CBMG's C-TIL051, a tumor-infiltrating lymphocyte (TIL) therapy, in advanced non-small cell lung cancer (NSCLC) patients that are relapsed or refractory to anti-PD-1 therapy.
Preclinical and early clinical data suggest that IL-15 can improve proliferation and persistence of cellular therapies including TIL, TCR, and CAR-T therapies to increase specific anti-tumor activity.
Under the new collaboration, CBMG will add NKTR-255 to its ongoing CBMG-sponsored Phase 1 clinical trial evaluating C-TIL051 in NSCLC patients who have relapsed on or were refractory to anti-PD-1 therapy.
The study is expected to enroll a total of 20 patients. Nektar will contribute NKTR-255 supply for the study. Nektar and CBMG will each maintain existing global rights to their respective investigational medicines.
For More Such Health News, visit rttnews.com
Nektar Therapeutics Promotes Chief Accounting Officer Jillian Thomsen To CFO
Japanese Market Notably Higher
Thai Bourse May Halt Losing Streak On Thursday
Australian Market Slightly Lower
Indonesia Shares Tipped To Open In The Green
Hong Kong Shares Poised To End Two-Day Slide
China Stock Market May Stop The Bleeding On Thursday
